These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 3221328)

  • 1. Testing for the equality of area under the curves when using destructive measurement techniques.
    Bailer AJ
    J Pharmacokinet Biopharm; 1988 Jun; 16(3):303-9. PubMed ID: 3221328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomization tests for assessing the equality of area under curves for studies using destructive sampling.
    Bailer AJ; Ruberg SJ
    J Appl Toxicol; 1996; 16(5):391-5. PubMed ID: 8889790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A note on testing areas under the curve when using destructive measurement techniques.
    Heinzl H
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):651-5. PubMed ID: 9300355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of pseudo-profiles in organ pharmacokinetics and toxicokinetics.
    Mager H; Göller G
    Stat Med; 1995 May 15-30; 14(9-10):1009-24. PubMed ID: 7569497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
    Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG
    Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid.
    Tzimas G; Nau H; Hendrickx AG; Peterson PE; Hummler H
    Teratology; 1996 Nov; 54(5):255-65. PubMed ID: 9035347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary, secondary, and tertiary metabolite kinetics.
    St-Pierre MV; Xu X; Pang KS
    J Pharmacokinet Biopharm; 1988 Oct; 16(5):493-527. PubMed ID: 3199316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study.
    Liao JJ
    Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
    Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient pharmacokinetic modeling of complex clinical dosing regimens: the universal elementary dosing regimen and computer algorithm EDFAST.
    Sebaldt RJ; Kreeft JH
    J Pharm Sci; 1987 Feb; 76(2):93-100. PubMed ID: 3572761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing pharmacokinetics of different doses of fosfomycin in laboratory rats enables adequate exposure for pharmacodynamic models.
    Poeppl W; Lingscheid T; Bernitzky D; Donath O; Reznicek G; Zeitlinger M; Burgmann H
    Pharmacology; 2014; 93(1-2):65-8. PubMed ID: 24503567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extension of Satterthwaite's approximation applied to pharmacokinetics.
    Nedelman JR; Jia X
    J Biopharm Stat; 1998 May; 8(2):317-28. PubMed ID: 9598425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative computer simulation study of three different sparse-sampling methods for the estimation of steady-state area under the concentration-time curve (AUC) and maximum concentration (Cmax) in toxicokinetics.
    Mahmood I
    J Pharm Sci; 1997 May; 86(5):579-83. PubMed ID: 9145382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sampling strategies to estimate the area under the concentration-time curve. Biases and a proposed more accurate method.
    Tsuruta H; Fukumoto M; Bax L; Kohno A; Morishita Y
    Methods Inf Med; 2012; 51(5):383-94. PubMed ID: 22614791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.